BreezeBio

BreezeBio is a biotechnology company dedicated to the development of next-generation adeno-associated virus (AAV) gene therapies. Co-founded by pioneers in the field, including Dr. Guangping Gao and Dr. Jun Xie from UMass Chan Medical School, the company focuses on overcoming the limitations of current viral delivery vectors. BreezeBio utilizes a proprietary platform to engineer novel AAV capsids designed for superior tissue specificity, reduced immunogenicity, and enhanced manufacturing efficiency. Their primary therapeutic focus is on addressing unmet medical needs in central nervous system (CNS) disorders and other rare genetic conditions. By optimizing the delivery vehicle, BreezeBio aims to provide safer and more effective genetic medicines for patients worldwide.